The Paris Region, without a doubt, is one of the world’s foremost centers for life science and health tech, drawing increasing interest from major pharmaceutical companies and innovative startups alike. Industry giants such as Sanofi, Servier and Ipsen are all quite happy to have an office in Paris, recognizing its strategic location and advantages in terms of investment and R&D. All in all, the health industry in Paris in booming. In fact, the Paris Region has secured the largest amount of venture capital (VC) funding in healthcare across the European Union in the span of just a few years. Paris’s central location in Western Europe adds to its appeal as it offers a high level of connectivity to other major cities via both train and plane. This geographical advantage is coupled with a strong academic tradition. Institutions like Paris Saclay University, ranked 1st worldwide in mathematics, and other prestigious universities like Sorbonne and PSL, contribute to a strong foundation for research and innovation. The Paris Region's attractiveness for foreign direct investments (FDI) in research and development (R&D) and corporate projects is also notable. According to the Global Cities Investment Monitor 2022, Paris ranks as the top destination worldwide for FDI in R&D and corporate projects. A key component of Paris’s health industry’s success remains its network of specialized clusters and communities. Genopole, located in Evry Courcouronnes, is a leading scientific campus and business cluster dedicated to biotechnologies. It makes waves in the field of genomics on account of its 73 companies and 16 academic laboratories focused on cell and gene therapies, diagnostic solutions, and foodtech. The Paris Saclay Cancer Cluster, an initiative supported by France 2030, pioneers groundbreaking treatments in oncology. This cluster aims to enhance the precision and efficiency of cancer treatment by consolidating expertise in a patient-centric ecosystem.